SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Capricor Therapeutics, Inc. – ‘8-K’ for 8/19/20 – ‘EX-3.1’

On:  Tuesday, 8/25/20, at 4:30pm ET   ·   For:  8/19/20   ·   Accession #:  1104659-20-98381   ·   File #:  1-34058

Previous ‘8-K’:  ‘8-K’ on / for 8/6/20   ·   Next:  ‘8-K’ on / for 11/9/20   ·   Latest:  ‘8-K’ on / for 4/29/24   ·   17 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/25/20  Capricor Therapeutics, Inc.       8-K:1,5,9   8/19/20    2:31K                                    Toppan Merrill/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     17K 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML      8K 


‘EX-3.1’   —   Articles of Incorporation/Organization or Bylaws


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT

 

OF THE BYLAWS OF

 

CAPRICOR THERAPEUTICS, INC.

 

The undersigned, Anthony Bergmann, hereby certifies that:

 

1.       He is the duly elected, qualified, and acting Chief Financial Officer of Capricor Therapeutics, Inc., a Delaware corporation formerly known as SMI Products, Inc. (the “Corporation”).

 

2.       The Bylaws of the Corporation (the “Bylaws”) were amended, effective August 20, 2020, in accordance with Section 8.9 thereof by the Board of Directors of the Corporation as follows:

 

ARTICLE IX

 

FORUM

 

SECTION 9.01 Forum for Certain Disputes. Unless the Corporation consents in writing to the selection of an alternative forum, (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owned by any director, officer, stockholder or employee of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the Certificate of Incorporation or these Bylaws (as either may be amended or restated) or (iv) any action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware shall, to the fullest extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware or, if such court does not have subject matter jurisdiction thereof, the federal district court of the State of Delaware. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any claims under the Securities Act of 1933, as amended, or any successor thereto. Nothing herein contained shall be construed to preclude stockholders that assert claims under the Securities Exchange Act of 1934, as amended, or any successor thereto, from bringing such claims in state or federal court, subject to applicable law. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article IX.

 

[Signature Page Follows]

 

 C: 

 

 

 

Executed on August 20, 2020.

 

  /s/ Anthony Bergmann
  Anthony Bergmann, Chief Financial Officer

 

 C: 

 


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on:8/25/20None on these Dates
8/20/20
For Period end:8/19/20
 List all Filings 


17 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/11/24  Capricor Therapeutics, Inc.       10-K       12/31/23   58:7.2M                                   Toppan Merrill Bridge/FA
 2/16/24  Capricor Therapeutics, Inc.       S-8         2/16/24    4:155K                                   Toppan Merrill Bridge/FA
11/14/23  Capricor Therapeutics, Inc.       10-Q        9/30/23   51:5.8M                                   Toppan Merrill Bridge/FA
 8/08/23  Capricor Therapeutics, Inc.       10-Q        6/30/23   51:5.4M                                   Toppan Merrill Bridge/FA
 5/12/23  Capricor Therapeutics, Inc.       10-Q        3/31/23   49:4.8M                                   Toppan Merrill Bridge/FA
 3/17/23  Capricor Therapeutics, Inc.       10-K       12/31/22   58:7.3M                                   Toppan Merrill Bridge/FA
 1/31/23  Capricor Therapeutics, Inc.       S-8         1/31/23    4:145K                                   Toppan Merrill Bridge/FA
11/10/22  Capricor Therapeutics, Inc.       10-Q        9/30/22   53:5.2M                                   Toppan Merrill Bridge/FA
 8/12/22  Capricor Therapeutics, Inc.       10-Q        6/30/22   51:4.9M                                   Toppan Merrill Bridge/FA
 5/11/22  Capricor Therapeutics, Inc.       10-Q        3/31/22   50:4.3M                                   Toppan Merrill Bridge/FA
 3/11/22  Capricor Therapeutics, Inc.       10-K       12/31/21   59:7.3M                                   Toppan Merrill Bridge/FA
 2/17/22  Capricor Therapeutics, Inc.       S-8         2/17/22    4:163K                                   Toppan Merrill Bridge/FA
 6/15/21  Capricor Therapeutics, Inc.       S-3/A                  2:711K                                   Toppan Merrill/FA
 3/16/21  Capricor Therapeutics, Inc.       S-3                    3:752K                                   Toppan Merrill/FA
 3/15/21  Capricor Therapeutics, Inc.       10-K       12/31/20   58:5.3M                                   Toppan Merrill/FA
 2/12/21  Capricor Therapeutics, Inc.       S-8         2/12/21    3:95K                                    Toppan Merrill/FA
11/13/20  Capricor Therapeutics, Inc.       10-Q        9/30/20   55:4.4M                                   Toppan Merrill/FA
Top
Filing Submission 0001104659-20-098381   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 4:50:10.2pm ET